Equities research analysts predict that Celgene Co. (NASDAQ:CELG) will announce $3.97 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have provided estimates for Celgene’s earnings. The highest sales estimate is $4.02 billion and the lowest is $3.94 billion. Celgene reported sales of $3.48 billion during the same quarter last year, which would suggest a positive year over year growth rate of 14.1%. The firm is scheduled to report its next earnings results on Thursday, January 24th.

On average, analysts expect that Celgene will report full year sales of $15.20 billion for the current fiscal year, with estimates ranging from $15.07 billion to $15.26 billion. For the next year, analysts anticipate that the firm will post sales of $16.91 billion, with estimates ranging from $16.49 billion to $17.26 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Celgene.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.02 by $0.27. Celgene had a net margin of 19.64% and a return on equity of 108.76%. The business had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.83 billion.

CELG has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Celgene from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. Mizuho set a $117.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Tuesday, October 30th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research note on Thursday, October 11th. Leerink Swann set a $112.00 price objective on shares of Celgene and gave the company a “hold” rating in a research note on Friday, October 26th. Finally, UBS Group set a $94.00 price objective on shares of Celgene and gave the company a “buy” rating in a research note on Saturday, October 27th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $116.99.

NASDAQ CELG traded down $2.65 on Tuesday, reaching $66.75. The company’s stock had a trading volume of 7,827,130 shares, compared to its average volume of 6,509,176. Celgene has a twelve month low of $66.63 and a twelve month high of $110.81. The company has a current ratio of 2.13, a quick ratio of 1.99 and a debt-to-equity ratio of 4.06. The company has a market capitalization of $48.70 billion, a price-to-earnings ratio of 9.76, a PEG ratio of 0.43 and a beta of 1.53.

Institutional investors have recently bought and sold shares of the company. Johnson Financial Group Inc. lifted its holdings in Celgene by 4.5% during the 2nd quarter. Johnson Financial Group Inc. now owns 13,100 shares of the biopharmaceutical company’s stock worth $1,040,000 after buying an additional 567 shares in the last quarter. Wetherby Asset Management Inc. lifted its holdings in Celgene by 5.4% during the 2nd quarter. Wetherby Asset Management Inc. now owns 11,857 shares of the biopharmaceutical company’s stock worth $942,000 after buying an additional 603 shares in the last quarter. Tompkins Financial Corp lifted its holdings in Celgene by 3.8% during the 2nd quarter. Tompkins Financial Corp now owns 18,059 shares of the biopharmaceutical company’s stock worth $1,434,000 after buying an additional 656 shares in the last quarter. Hills Bank & Trust Co. lifted its holdings in Celgene by 4.9% during the 3rd quarter. Hills Bank & Trust Co. now owns 14,255 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 672 shares in the last quarter. Finally, Coastline Trust Co lifted its holdings in Celgene by 14.5% during the 2nd quarter. Coastline Trust Co now owns 5,370 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 680 shares in the last quarter. 73.87% of the stock is owned by institutional investors and hedge funds.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Read More: Hedge Funds Explained

Get a free copy of the Zacks research report on Celgene (CELG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.